Common-Size Income Statement
Quarterly Data
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Cash Flow Statement
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Debt to Equity since 2012
- Price to Earnings (P/E) since 2012
- Price to Operating Profit (P/OP) since 2012
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
Income statement item | Description | The company |
---|---|---|
Operating earnings | The net result for the period of deducting operating expenses from operating revenues. | AbbVie Inc. operating earnings as a percentage of net revenues increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024. |
Earnings (loss) before income tax (expense) benefit | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | AbbVie Inc. earnings (loss) before income tax (expense) benefit as a percentage of net revenues increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024 not reaching Q1 2024 level. |
Net earnings (loss) attributable to AbbVie Inc. | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | AbbVie Inc. net earnings (loss) attributable to AbbVie Inc. as a percentage of net revenues decreased from Q1 2024 to Q2 2024 but then increased from Q2 2024 to Q3 2024 not reaching Q1 2024 level. |